Sidley Austin represented ADARx Pharmaceuticals in the financing. ADARx Pharmaceuticals, Inc. announced its successful close of an oversubscribed $200 million Series C financing. The proceeds from...
ADARx Pharmaceuticals’ $200 Million Series C Financing Round
ADARx Pharmaceuticals’ US$46 Million Series B-1 Financing
Sidley represented ADARx Pharmaceuticals, Inc. on the deal. ADARx Pharmaceuticals, Inc., a clinical-stage biotechnology company developing RNA-targeting therapeutics, announced its US$46 million Series B-1 financing. The proceeds...